New Antibiotic Against Serious Infections Receives First Approval In Europe
Nov 21st 2008Drug InformationMRSA / Drug Resistance
Swissmedic, the Swiss agency for therapeutic products, has approved ZEVTERA? (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone. Ceftobiprole is licensed from and co-developed with Basilea Pharmaceutica Ltd. Janssen-Cilag will market ceftobiprole in Switzerland under the trade name ZEVTERA?.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
